Latest news with #TripleNegativeBreastCancer
Health Line
5 days ago
- Health
- Health Line
The Future of Treatments for Triple-Negative Breast Cancer
This type of breast cancer can be difficult to treat, but advances in therapeutic approaches are promising. Triple-negative breast cancer (TNBC) is a rare type of breast cancer that doesn't respond to common hormone-based therapies. However, other treatments are available. 'Triple-negative' describes cancer cells that test negative for three types of receptors: estrogen progesterone HER2 Because of its triple-negative status, TNBC doesn't respond to treatments that target estrogen or progesterone receptors. It also doesn't respond to the various HER2 cancer treatments. However, TNBC is sensitive to chemotherapy and immunotherapy, which can shrink tumors so they're easier to remove surgically. About 10% to 15% of all breast cancer types are of the triple-negative type. Most instances of TNBC are invasive ductal carcinoma, but ductal carcinoma in situ can also be estrogen-receptor and progesterone-receptor negative. The cell type, not the location, determines whether breast cancer is TNBC. Black and Latinx people are more likely to develop TNBC than those of other ethnicities. A 2021 study found that Black women were 2.7 times more likely than white women to receive a TNBC diagnosis. Many Black females don't have access to the insurance or resources they need to manage this type of cancer. They may experience delays between diagnosis and treatment and challenges communicating with doctors. People with mutations on their BRCA gene, especially on the BRCA1 gene, are also at risk for this type of breast cancer, as are those younger than age 50. Types of treatment Even though TBNC is harder to treat compared to other types of breast cancer, treatments continue to evolve. Chemotherapy A common TNBC treatment strategy is to begin with chemotherapy, either alone or in combination with an immunotherapy drug. This helps shrink tumors so they're easier to remove with surgery. It can also shrink affected lymph nodes. Some research suggests that neoadjuvant chemotherapy (chemotherapy that occurs before other treatments) can eliminate invasive breast cancer in about 30% to 50% of cases. Other studies have found that it is effective in over 58% of those with TNBC. Research has found that when chemo can eliminate TNBC, the 5-year event-free survival rate is 92% and the 10-year event-free survival rate is 87%. Event-free survival includes cancer recurrence and further complications. However, this is dependent upon the stage of the tumor. Your doctor might prescribe additional chemotherapy treatment after surgery. Chemotherapy after surgery is known as adjuvant chemotherapy and is performed to reduce the likelihood of a cancer recurrence. Surgery Surgery can be performed before or after chemotherapy. When an early stage TNBC tumor is small enough, treatment may begin with surgery. The surgeon will remove the tumor and check your lymph nodes. Surgery might involve: a lumpectomy, which removes the tumor while preserving breast tissue a mastectomy, which removes the entire breast a sentinel lymph node biopsy, which removes nearby lymph nodes Additional treatment may be needed after surgery to help improve outcomes. Immunotherapy Immunotherapy works by boosting your immune system and teaching it to target cancer cells by controlling the action of protein checkpoints that turn your immune response on or off. It can be used before or after surgery. Pembrolizumab (Keytruda) is an immunotherapy drug that targets the immune cell protein PD-1. This protein usually stops immune cells from attacking. Pembrolizumab prevents PD-1 from blocking immune system cells so they can attack breast cancer cells. About 1 in 5 instances of TNBC have the PD-1 protein. Targeted therapy Targeted therapy works by targeting specific proteins in breast cancer cells to slow or stop the cancer from growing and spreading. This type of treatment can also help you live longer. Targeted therapy can be used to help other types of treatment work better or in place of other interventions that aren't effective. One type of targeted therapy is an antibody drug conjugate, such as sacituzumab govitecan (Trodelvy). This attaches itself to a specific protein in the cancer cell to directly deliver chemotherapy to it. If you have a BRCA mutation, your doctor may recommend taking olaparib (Lynparza) or talazoparib (Talzenna). Radiation Radiation treatment is recommended if you elect for breast conservation with a lumpectomy. It can also be used if you've had a mastectomy with positive lymph nodes. Radiation treatment uses high energy radiation that destroys remaining breast cancer cells. There are two types of radiation treatment: external beam radiation and internal radiation. During external beam radiation, a machine outside your body will direct radiation to the target area. For brachytherapy, or internal radiation, a healthcare professional will place radioactive material inside your body, next to the cancer site. Clinical trials Clinical trials are research studies using human volunteers. Trials are available for all stages of cancer. If you're part of a clinical trial, you might have advanced access to new treatments. By participating in a trial, you will also contribute to improving medical knowledge and progress in cancer treatments. You can discuss the option of a clinical trial with your doctor. You can also find more information through the following online resources: Treatment considerations Your unique circumstances determine the approach to TNBC treatment. Your care team will develop a specific treatment plan based on your situation. In some cases, you'll have surgery first to remove the cancerous tumor, followed by other treatments to reduce the risk of cancer coming back, helping prolong your life. In other cases, you'll undergo treatment first to help shrink the tumors before having them surgically removed. Follow-up treatment may then also be recommended after surgery. People diagnosed with stage 4 TNBC rarely undergo surgery or radiation. However, they may be prescribed stronger types of chemotherapy, targeted therapy, or immunotherapy — or different combinations of these treatments — to help improve outcomes. Personalized treatment approach Newer treatment options, such as targeted therapy and immunotherapy, have advanced the personalized approach to TNBC treatment. The BRCA mutation may present an opportunity for a precision treatment approach. It occurs in about 20% to 30% of TNBC cancer instances and responds to treatment using poly (ADP-ribose) polymerase (PARP) inhibitors. Using pembrolizumab to target PD-1 is another personalized approach for TNBC cancer cells with this protein. For more advanced TNBC where other treatments aren't effective, using sacituzumab govitecan can be another personalized option. Research is also ongoing to determine whether the aggressive nature of TNBC in Black women is because of health issues such as obesity or factors like socioeconomic status, healthcare access, or cultural practices. This may lead to much-needed precision treatment approaches for Black women. However, TNBC can still be challenging to treat. This is mainly due to its aggressive nature and lack of certain protein receptors. There are also few outlook (related to a person's overall outcome, regardless of therapy) and predictive (related specifically to treatment outcomes) biomarkers. Outlook The National Cancer Institute (NCI) maintains a database called the Surveillance, Epidemiology, and End Results Program (SEER). The SEER database tracks 5-year relative survival rates by grouping cancers into categories based on how far they've spread. A relative survival rate compares a person with cancer against the overall population. For example, if you have breast cancer with a 90% 5-year relative survival rate, you're 90% as likely to live for 5 years as someone without this disease. According to the American Cancer Society, the SEER 5-year relative survival rates for TNBC are: 92% for localized (cancer is contained within the breast) 67% for regional (cancer is located in the breast and nearby lymph nodes and tissues) 15% for distant (cancer is located in distant areas like the liver, bones, or lungs) 78% for all stages combined These percentages have increased slightly in recent years, as treatment methods continue to evolve.
Globe and Mail
05-02-2025
- Business
- Globe and Mail
Triple Negative Breast Cancer FDA Approvals, Emerging Therapies, Pipeline Insights and Companies
DelveInsight's, ' Triple Negative Breast Cancer Pipeline Insight ' report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Triple Negative Breast Cancer pipeline landscape. It covers the Triple Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Triple Negative Breast Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Triple Negative Breast Cancer Pipeline Outlook Key Takeaways from the Triple Negative Breast Cancer Pipeline Report In January 2025:- Merck Sharp & Dohme LLC- The purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy and pembrolizumab vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC). In January 2025:- AstraZeneca:- This is a Phase IB/II, 2-stage, open-label, multicenter study to determine the efficacy and safety of durvalumab in combination with novel oncology therapies (i.e. therapies designed for immune modulation) with or without paclitaxel and durvalumab + paclitaxel as first-line treatment in patients with metastatic triple negative breast cancer (TNBC). The study is designed to concurrently evaluate potential novel treatment combinations with clinical promise using a 2-stage approach. The study will use a Simon 2-Stage design to evaluate which cohorts may proceed to expansion. In January 2025: Mabwell (Shanghai) Bioscience Co., Ltd.- This study is a Phase 2, open-label,multicenter study designed to evaluate the efficacy and safety of 9MW2821monotherapy or combined with PD-1 inhibitor in locally advanced or metastatic Triple-Negative Breast Cancer. DelveInsight's Triple Negative Breast Cancer Pipeline analysis depicts a robust space with 75+ active players working to develop 80+ pipeline treatment therapies. The leading Triple Negative Breast Cancer Companies such as Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others. Promising Triple Negative Breast Cancer Pipeline Therapies such as Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others. Stay ahead with the most recent pipeline outlook for Triple Negative Breast Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Triple Negative Breast Cancer Treatment Drugs Triple Negative Breast Cancer Emerging Drugs Profile Camrelizumab: Jiangsu HengRui Medicine Camrelizumab (Airuika) is a humanized monoclonal antibody acts as immunomodulatory agent. It is formulated as solution for intravenous route. Camrelizumab is indicated as third-line treatment for recurrent or refractory classical hodgkin's lymphoma, advanced hepatocellular carcinoma patients with oxaliplatin system chemotherapy, combined with pemetrexed and carboplatin for epidermal growth factor receptor (EGFR) gene mutation negative and anaplastic lymphoma kinase (ALK) negative, non-resectable locally advanced or metastatic first-line treatment of non-squamous non-small cell lung cancer (NSCLC), locally advanced or metastatic esophageal squamous cell carcinoma patients who have previously received first-line chemotherapy and whose disease has progressed or become intolerable and for the treatment of patients with advanced nasopharyngeal carcinoma who had disease progression after previous second-line and above chemotherapy or intolerable treatment. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Triple Negative Breast Cancer. SKB264: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKB264 is an innovative TROP2-directed ADC which was developed by OptiDC, a well-known international ADC R&D platform of Kelun-Biotech, using a proprietary payload-linker strategy (Kthiol design strategy) that achieves an optimized balance of ADC safety and efficacy by combining novel irreversible antibody conjugation chemistry, pH-sensitive payload release mechanisms, and site-specific moderately potent toxin molecules with a DAR of 7.4 (novel topoisomerase I inhibitors). SKB264 has received Breakthrough Therapy Designations (BTDs) from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of locally advanced or metastatic triple-negative breast cancer. AK117: Akeso Biopharma AK117, independently developed by Akeso, is a next generation of humanized lgG4 anti-CD47 antibody without hemagglutination effect. AK117 can bind to CD47 expressed on tumor cells and block the interaction between CD47 and SIRPα, in order to enhance the phagocytic activity of phagocytes on tumor cells, thereby inhibiting the growth of tumors. Currently, the drug is in Phase II stage of clinical trial evaluation for the treatment of Triple Negative Breast Cancer. PLX038: ProLynx PLX038 is a long-acting prodrug of the topoisomerase 1 (Top1) inhibitor, SN-38, which is also the active component of anti-cancer agents irinotecan and the ADC SC. Top1 inhibitors cause DNA breaks and kill tumors that are unable to repair the damage. Previously, Curie researchers showed that about one-third of TNBC patients have defects in DNA damage repair, and should respond to an effective SN-38-based therapy (Coussy et al., 2020). In PLX038, SN-38 is covalently bound to a circulating nanoparticle and is slowly released to provide free SN-38 with a long half-life, low Cmax, and high exposure – important facets for optimal safety and efficacy. Importantly, in preclinical studies PLX038 was shown to accumulate and be retained in solid tumors, where it slowly releases its SN-38. Currently, the drug is in Phase II stage of clinical trial evaluation for the treatment of Triple Negative Breast Cancer. PMD-026: Phoenix Molecular Designs PhoenixMD's lead candidate, PMD-026, is the first RSK inhibitor being developed for the treatment of TNBC. It is a pill that is convenient for patients as opposed to intravenous delivery, the mode most commonly used to deliver chemotherapy. PMD-026 was designed for TNBC because RSK2 was specifically identified as the key kinase that drives the growth of this breast cancer subtype5, 6. PMD-026 is well-tolerated in breast cancer patients and can stop tumor growth for up to 5 months based on Phase 1 data. PFS in women with TNBC is three times longer for patients that express high levels of RSK2 activation as compared to those with low RSK2 activation. Preclinical data shows PMD-026 has the potential to be a platform technology for chemotherapy, hormone therapy and/or immunotherapy sensitization for a wide range of refractory cancers in the future. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Triple Negative Breast Cancer. Triple Negative Breast Cancer Companies Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others Triple Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration Oral Parenteral intravenous Subcutaneous Topical. Triple Negative Breast Cancer Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Unveil the future of Triple Negative Breast Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Triple Negative Breast Cancer Market Drivers and Barriers Scope of the Triple Negative Breast Cancer Pipeline Report Coverage- Global Triple Negative Breast Cancer Companies- Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others. Triple Negative Breast Cancer Pipeline Therapies- Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others. Triple Negative Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Triple Negative Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Triple Negative Breast Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Triple Negative Breast Cancer Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Triple Negative Breast Cancer: Overview Pipeline Therapeutics Therapeutic Assessment Triple Negative Breast Cancer – DelveInsight's Analytical Perspective Late Stage Products (Phase III) Camrelizumab: Jiangsu HengRui Medicine Drug profiles in the detailed report….. Mid Stage Products (Phase II) AK117: Akeso Biopharma Drug profiles in the detailed report….. Early Stage Products (Phase I) PMD-026: Phoenix Molecular Designs Drug profiles in the detailed report….. Inactive Products Triple Negative Breast Cancer Key Companies Triple Negative Breast Cancer Key Products Triple Negative Breast Cancer- Unmet Needs Triple Negative Breast Cancer- Market Drivers and Barriers Triple Negative Breast Cancer- Future Perspectives and Conclusion Triple Negative Breast Cancer Analyst Views Triple Negative Breast Cancer Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 9650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
